Sudo Biosciences Raises $116M Series B Financing To Advance Potential Best-In-Class Tyk2 Therapeutics Programs Into The Clinic
Amount Raised
$116 Million
Round Type
Series B
CarmelBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnology ResearchInvestors
Description
Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital. The Company has raised a total of $157 million funding since its founding in 2020.
Quick answer
Sudo Biosciences raised $116 Million in a Series B round, dated December 20, 2023. Investors: TPG Angelo Gordon, Velosity Capital, Frazier Life Sciences, Eventide Asset Management, Monograph Capital, Surveyor Capital, Sanofi Ventures and The Rise Fund. Sudo Biosciences is based in Carmel, Indiana, United States.
- How much did Sudo Biosciences raise?
- Sudo Biosciences raised $116 Million in a Series B round on December 20, 2023.
- Who invested in Sudo Biosciences?
- TPG Angelo Gordon, Velosity Capital, Frazier Life Sciences, Eventide Asset Management, Monograph Capital, Surveyor Capital, Sanofi Ventures and The Rise Fund are named as investors in this round.
- What does Sudo Biosciences do?
- Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 inhibitors to transform the treatment of immune-mediated diseases.
- Where is Sudo Biosciences based and how big is it?
- Sudo Biosciences is based in Carmel, Indiana, United States. Fundz records about 24 employees.
- Who are the decision-makers at Sudo Biosciences?
- Fundz holds 1 contact at Sudo Biosciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Sudo Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Adipo Therapeutics raised $1.9M (Seed) on January 31, 2024.
- Enterprise Therapeutics Ltd raised $33M (Series B) on January 30, 2024.
- OnCusp Therapeutics raised $100M (Series A) on January 4, 2024.
- Liquidia raised $100M (Funding Round) on January 4, 2024.
- Os Therapies raised $700K on December 8, 2023.
- Cartesian Therapeutics, Inc. raised $60M on November 13, 2023.
Who to call at Sudo Biosciences, and when
A new round usually means Sudo Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sudo Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sudo Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sudo Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sudo Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSudo Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.